Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
73.25
+6.15 (9.17%)
At close: Jul 28, 2025, 4:00 PM HKT
9.17%
Market Cap14.17B
Revenue (ttm)n/a
Net Income (ttm)-310.94M
Shares Out193.36M
EPS (ttm)-2.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,879,828
Average Volumen/a
Open67.10
Previous Close67.10
Day's Range63.20 - 73.75
52-Week Range67.10 - 79.60
Betan/a
RSIn/a
Earnings Daten/a

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 195
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9887
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.